Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $ ...

Across the recent three months, 5 analysts have shared their insights on Arcturus Therapeutics ARCT, expressing a variety ... With a high debt-to-equity ratio of 0.11, Arcturus Therapeutics ...

ARCT has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on ...

The firm increased its portfolio allocation in ARCT by 38.78% over the last quarter. FKASX - Federated Kaufmann Small Cap Fund Shares holds 2,198K shares representing 8.11% ownership of the company.

(RTTNews) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization ...

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a self-amplifying mRNA COVID-19 vaccine, for individuals 18 ...

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a self-amplifying mRNA COVID-19 vaccine, for individuals 18 ...

The company's pipeline includes ARCT-810, a treatment for ornithine transcarbamylase deficiency in Phase 2 trials, ARCT-154, a COVID-19 vaccine candidate in Phase 3 trials in Vietnam, and ARCT-032 ...